Niraparib / Abiraterone 100/500mg
| Product Overview | |
| Generic Name | Niraparib / Abiraterone 100/500mg |
| Brand Name(s) | Akeega® |
| Form | 60 Film-coated tablets; oral use |
| Strength | 50 mg/500 mg; 100 mg/500 mg |
| Therapeutic Class | Antineoplastic combination; PARP inhibitor + androgen biosynthesis inhibitor |
| ATC Code | L01XK52 |
| Manufacturing & Regulatory | |
| Manufacturer | Janssen Biotech, Inc |
| Country | Product of France |
| GMP Compliance | WHO-GMP, EU-GMP |
| COFEPRIS | Under Registration (2025) |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 30 Months |
| Storage | store at 20°C to 25°C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Supplied per batch upon request |
Description
a fixed-dose oral oncology combination containing niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 androgen-biosynthesis inhibitor. It is used with prednisone or prednisolone for adult male patients with BRCA-mutated metastatic prostate cancer, including metastatic castration-resistant prostate cancer
